Inovelon (Rufinamide)

Rufinamide modulates voltage‑gated sodium channels in neuronal membranes, prolonging their inactivated state. This action stabilizes neuronal excitability and reduces the rapid firing of neurons that generate seizures, thereby contributing to seizure control in epilepsy patients.

The dosage of Inovelon is individualized and determined by the prescribing healthcare professional based on the patient’s age, weight, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Rufinamide in pregnancy and lactation are limited. The medication should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended unless the benefits outweigh the possible risks, and a healthcare provider should be consulted.

To order Inovelon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Inovelon (Rufinamide) offers a distinct mechanism by targeting voltage‑gated sodium channels, which can be advantageous for patients with Lennox‑Gastaut syndrome who have not responded to other agents. Compared with broader‑spectrum antiepileptics, Rufinamide may have a different side‑effect profile and fewer drug‑enzyme interactions, but individual response varies.

Inovelon tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect from moisture and light. Keep the medication out of reach of children and do not use it after the expiration date.

Inovelon is taken orally as a tablet. It should be swallowed whole with water, preferably at the same times each day to maintain consistent blood levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, significant depression or suicidal thoughts, and hepatic dysfunction. Patients should be monitored for any signs of these conditions and seek immediate medical attention if they occur.

Inovelon is contraindicated in patients with known hypersensitivity to Rufinamide or any of its excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled depression, or those taking strong enzyme‑inducing antiepileptics that may markedly reduce its effectiveness.